CA3058375C - NIRAPARIB COMPOSITIONS - Google Patents
NIRAPARIB COMPOSITIONSInfo
- Publication number
- CA3058375C CA3058375C CA3058375A CA3058375A CA3058375C CA 3058375 C CA3058375 C CA 3058375C CA 3058375 A CA3058375 A CA 3058375A CA 3058375 A CA3058375 A CA 3058375A CA 3058375 C CA3058375 C CA 3058375C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- piperidin
- phenyl
- indazole
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477411P | 2017-03-27 | 2017-03-27 | |
| US62/477,411 | 2017-03-27 | ||
| PCT/US2018/024603 WO2018183354A1 (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3058375A1 CA3058375A1 (en) | 2018-10-04 |
| CA3058375C true CA3058375C (en) | 2025-05-06 |
Family
ID=63676949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3058375A Active CA3058375C (en) | 2017-03-27 | 2018-03-27 | NIRAPARIB COMPOSITIONS |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11091459B2 (https=) |
| EP (1) | EP3600314A1 (https=) |
| JP (1) | JP2020512350A (https=) |
| KR (1) | KR20200014736A (https=) |
| CN (1) | CN110944638A (https=) |
| AU (2) | AU2018246214B2 (https=) |
| BR (1) | BR112019020211A2 (https=) |
| CA (1) | CA3058375C (https=) |
| EA (1) | EA201992177A1 (https=) |
| IL (1) | IL269630A (https=) |
| MX (1) | MX2019011496A (https=) |
| SG (1) | SG11201909011PA (https=) |
| TW (1) | TWI761476B (https=) |
| WO (1) | WO2018183354A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| BR112019020211A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro, Inc. | composições de niraparib |
| KR102582624B1 (ko) | 2017-04-24 | 2023-09-22 | 테사로, 인코포레이티드 | 니라파립의 제조 방법 |
| TWI879716B (zh) | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
| KR20250016494A (ko) | 2017-09-26 | 2025-02-03 | 테사로, 인코포레이티드 | 니라파립 제제 |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| SG11202002499TA (en) | 2017-10-06 | 2020-04-29 | Tesaro Inc | Combination therapies and uses thereof |
| AU2019215450A1 (en) | 2018-02-05 | 2020-08-27 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| WO2020072860A1 (en) * | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
| CA3087392A1 (en) | 2019-07-16 | 2021-01-16 | Apotex Inc. | Crystalline forms of niraparib tosylate |
| UY39201A (es) | 2020-05-08 | 2021-11-30 | Janssen Pharmaceutica Nv | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib |
| US20240325369A1 (en) | 2021-07-19 | 2024-10-03 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| CA3257870A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES |
| WO2024238587A1 (en) | 2023-05-17 | 2024-11-21 | Tesaro, Inc. | Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0606663D0 (en) | 2006-04-03 | 2006-05-10 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2007733B1 (en) | 2006-04-03 | 2016-05-25 | MSD Italia S.r.l. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| WO2008043024A2 (en) | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
| AR064777A1 (es) | 2007-01-10 | 2009-04-22 | Inst Di Reserche D Biolog Mole | Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp) |
| CA2702429A1 (en) * | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| ES2572652T3 (es) * | 2009-08-26 | 2016-06-01 | Cephalon, Inc. | Nuevas formas de un compuesto multicíclico |
| CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| US9738915B2 (en) | 2012-12-07 | 2017-08-22 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| US9191894B2 (en) * | 2013-07-23 | 2015-11-17 | Disney Enterprises, Inc. | Power saving for multi-hop communications |
| CA2935857C (en) | 2014-01-05 | 2020-12-15 | Washington University | Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor |
| WO2015164161A1 (en) | 2014-04-22 | 2015-10-29 | Calitor Sciences, Llc | Bicylcic pyrazolone compounds and methods of use |
| US10238630B2 (en) | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| KR102803917B1 (ko) | 2014-08-22 | 2025-05-07 | 파르마＆ 슈바이츠 게엠베하 | 루카파립의 고 용량 강도 정제 |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| PL3954690T3 (pl) | 2015-07-02 | 2023-08-14 | Acerta Pharma B.V. | Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu |
| KR20230042136A (ko) * | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| CN106496187A (zh) * | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106831708A (zh) | 2016-11-22 | 2017-06-13 | 西安泰科迈医药科技股份有限公司 | 一种新型口服抗癌药物Nirapairb的合成方法 |
| CN108201537A (zh) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| CN106854176A (zh) | 2016-12-21 | 2017-06-16 | 南京艾德凯腾生物医药有限责任公司 | 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| KR20190130625A (ko) | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| BR112019020211A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro, Inc. | composições de niraparib |
| KR102582624B1 (ko) | 2017-04-24 | 2023-09-22 | 테사로, 인코포레이티드 | 니라파립의 제조 방법 |
| TWI879716B (zh) | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
| CN108530425A (zh) | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| KR20250016494A (ko) | 2017-09-26 | 2025-02-03 | 테사로, 인코포레이티드 | 니라파립 제제 |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| SG11202002499TA (en) | 2017-10-06 | 2020-04-29 | Tesaro Inc | Combination therapies and uses thereof |
| SG11202006147SA (en) | 2017-12-27 | 2020-07-29 | Tesaro Inc | Methods of treating cancer |
| AU2019215450A1 (en) | 2018-02-05 | 2020-08-27 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| US20210347758A1 (en) * | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| CA3087392A1 (en) * | 2019-07-16 | 2021-01-16 | Apotex Inc. | Crystalline forms of niraparib tosylate |
-
2018
- 2018-03-27 BR BR112019020211-0A patent/BR112019020211A2/pt not_active Application Discontinuation
- 2018-03-27 WO PCT/US2018/024603 patent/WO2018183354A1/en not_active Ceased
- 2018-03-27 CA CA3058375A patent/CA3058375C/en active Active
- 2018-03-27 EA EA201992177A patent/EA201992177A1/ru unknown
- 2018-03-27 JP JP2019553055A patent/JP2020512350A/ja active Pending
- 2018-03-27 EP EP18774912.2A patent/EP3600314A1/en not_active Withdrawn
- 2018-03-27 AU AU2018246214A patent/AU2018246214B2/en active Active
- 2018-03-27 CN CN201880033357.6A patent/CN110944638A/zh active Pending
- 2018-03-27 TW TW107110575A patent/TWI761476B/zh active
- 2018-03-27 MX MX2019011496A patent/MX2019011496A/es unknown
- 2018-03-27 KR KR1020197031668A patent/KR20200014736A/ko not_active Ceased
- 2018-03-27 SG SG11201909011P patent/SG11201909011PA/en unknown
-
2019
- 2019-09-25 IL IL26963019A patent/IL269630A/en unknown
- 2019-09-26 US US16/584,401 patent/US11091459B2/en active Active
-
2021
- 2021-06-04 US US17/339,896 patent/US11673877B2/en active Active
- 2021-10-08 AU AU2021245223A patent/AU2021245223A1/en not_active Abandoned
-
2023
- 2023-05-01 US US18/310,238 patent/US20230416223A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL269630A (en) | 2019-11-28 |
| BR112019020211A2 (pt) | 2020-04-22 |
| EP3600314A1 (en) | 2020-02-05 |
| US20210403448A1 (en) | 2021-12-30 |
| WO2018183354A1 (en) | 2018-10-04 |
| AU2021245223A1 (en) | 2021-11-04 |
| TW201840315A (zh) | 2018-11-16 |
| KR20200014736A (ko) | 2020-02-11 |
| MX2019011496A (es) | 2020-01-23 |
| US11673877B2 (en) | 2023-06-13 |
| CA3058375A1 (en) | 2018-10-04 |
| JP2020512350A (ja) | 2020-04-23 |
| AU2018246214B2 (en) | 2021-07-08 |
| US20230416223A1 (en) | 2023-12-28 |
| SG11201909011PA (en) | 2019-10-30 |
| EA201992177A1 (ru) | 2020-02-25 |
| CN110944638A (zh) | 2020-03-31 |
| US11091459B2 (en) | 2021-08-17 |
| TWI761476B (zh) | 2022-04-21 |
| US20200017462A1 (en) | 2020-01-16 |
| AU2018246214A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11673877B2 (en) | Niraparib compositions | |
| US20240082231A1 (en) | Niraparib formulations | |
| EP3641742B1 (en) | Hydroxynorketamine for the use in the treatment of depression | |
| KR102116087B1 (ko) | 리카르바제핀 아세테이트를 포함하는 경구 투여형 | |
| EP2200599B1 (en) | 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss | |
| KR20260048646A (ko) | 엔독시펜을 제조 및 사용하는 방법 | |
| WO2015102826A1 (en) | Novel compositions | |
| US20060034911A1 (en) | New oral immediated release dosage form | |
| JP2019529502A (ja) | アルツハイマー病及びパーキンソン病を処置するための組成物及び方法 | |
| EP2976067B1 (en) | Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof | |
| KR101506627B1 (ko) | 아세브로필린 및 친수성 서방기제를 포함하는 서방형 약학 조성물 | |
| US20050118262A1 (en) | Controlled release formulation | |
| TW202327588A (zh) | 治療神經膠質母細胞瘤之方法 | |
| CN117412962A (zh) | 用酞嗪酮衍生物治疗病症的方法 | |
| CN116322653A (zh) | 包括酞嗪酮衍生物的药物组合物 | |
| BRPI0617184A2 (pt) | formulação de pralnacasan com liberação retardada | |
| CN108853033A (zh) | 一种喹硫平药物制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230327 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250227 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250227 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250321 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20250430 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20250506 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250530 |